You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
EPS創健科技(03860.HK)斥2.85億人幣收購三家臨床研究公司股權
EPS創健科技(03860.HK)公布,附屬於9月20日與公司關連人士益新國際醫藥科技訂立協議,以現金代價2.85億元人民幣,收購上海日新醫藥發展約95%股權、蘇州益新泰格約51%股權及北京格銳博約51%股權。交易完成後,三家公司將成為公司的間接非全資附屬,其財務業績、資產及負債將併入公司賬簿。 其中,上海日新醫藥發展主要從事臨床項目管理和監測、醫療數據分析和報告、患者招募和資源相關事宜的解決方案支持。 蘇州益新泰格主要從事臨床試驗數據處理與管理、統計分析與報告、醫療器械相關安全資訊翻譯、電子數據採集系統開發與支援、動態心電圖監測分析,目前由泰格醫藥(03347.HK)持股49%。 而北京格銳博則主要從事研究可行性研究等醫學監測、研究中心/研究人員選擇、隨機化中心、研究監測和質量控制、藥物研究和研究數據管理、註冊協助如申請準備、提交和諮詢、競爭性產品和市場研究、藥品法規諮詢和其他相關開發、營銷和諮詢服務。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account